100% agree, and the nominees that were appointed as on the vend...

100% agree, and the nominees that were appointed as on the vend of Didievi have contributed nothing to date as far as I am aware.

They are simply taking their director fees, and have introduced a new 'on site' assay technology which the company is paying a fee for. Who knows how accurate this is an whether there is any real value add for the company.

This is quite clearly now a shell. As a listed company with no money actually being spent on existing projects, I am deeply concerned with the cash burn, which is lining the directors pockets. I have no issue with electing to stop spending money on assets which have no potential, but if they are going back to searching for new assets, operating costs need to be kept to a minimum. It is in shareholders bests interests, we don't need another dilutive capital raise before the company has achieved anything.